Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

医学 奥马佐单抗 中止 慢性荨麻疹 皮肤病科 药品 梅德林 跨国公司 重症监护医学 内科学 药理学 免疫学 免疫球蛋白E 抗体 政治学 法学
作者
Reineke Soegiharto,Mehran Alizadeh Aghdam,Jennifer Astrup Sørensen,Esmee van Lindonk,Ferhan Bulut Demir,Nasser Mohammad Porras,Yoshimi Matsuo,Lea Kiefer,André C. Knulst,Marcus Maurer,Carla Ritchie,Michael Rudenko,Emek Kocatürk,Roberta Fachini Jardim Criado,Stamatios Gregoriou,Tatjana Bobylev,Andreas Kleinheinz,Shunsuke Takahagi,Michihiro Hide,Ana M. Giménez‐Arnau
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:160 (9): 927-927 被引量:5
标识
DOI:10.1001/jamadermatol.2024.2056
摘要

Importance Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation. Objective To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population. Design, Setting, and Participants This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab. Main Outcomes and Measures Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation. Results In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness. Conclusion and Relevance This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
寒冷的灵完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
星辰大海应助hahaer采纳,获得10
3秒前
杨过和雕关注了科研通微信公众号
4秒前
5秒前
一生所爱完成签到,获得积分10
5秒前
5秒前
曾经如是发布了新的文献求助10
5秒前
清零完成签到,获得积分10
6秒前
7秒前
8秒前
9秒前
10秒前
11秒前
立仔发布了新的文献求助10
12秒前
ShengzhangLiu发布了新的文献求助10
12秒前
12秒前
SYLH应助科学采纳,获得10
12秒前
13秒前
Salt发布了新的文献求助10
14秒前
JamesPei应助科研眼镜蛇采纳,获得10
15秒前
听安完成签到,获得积分10
16秒前
77关闭了77文献求助
16秒前
充电宝应助lzr采纳,获得10
17秒前
苗苗发布了新的文献求助10
17秒前
称心凡霜完成签到,获得积分10
22秒前
23秒前
一颗石榴完成签到,获得积分10
23秒前
温离完成签到,获得积分10
24秒前
ZZ发布了新的文献求助10
27秒前
玉昆完成签到 ,获得积分10
28秒前
今后应助吴玉婷采纳,获得30
28秒前
立仔完成签到,获得积分10
29秒前
Zoe_Zhang完成签到 ,获得积分10
30秒前
31秒前
重要的秋尽完成签到,获得积分10
32秒前
111发布了新的文献求助10
32秒前
量子星尘发布了新的文献求助10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975458
求助须知:如何正确求助?哪些是违规求助? 3519866
关于积分的说明 11199996
捐赠科研通 3256213
什么是DOI,文献DOI怎么找? 1798133
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305